Effect of Turmeric on Diabetic Nephropathy

This study has been completed.
Sponsor:
Collaborator:
Shiraz University of Medical Sciences
Information provided by:
Shaheed Faghihi Hospital
ClinicalTrials.gov Identifier:
NCT01015937
First received: November 16, 2009
Last updated: November 17, 2009
Last verified: November 2009
  Purpose

The purpose of this study is to investigate whether turmeric is effective in improvement of diabetic nephropathy and in decrease in the amount of proteinuria and cytokine levels.


Condition Intervention
Diabetic Nephropathy
Proteinuria
Drug: Turmeric extract
Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Shaheed Faghihi Hospital:

Enrollment: 50
Study Start Date: March 2008
Study Completion Date: August 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Turmeric

diabetic nephropathy patient

more than 300 mg/proteinuria

Drug: Turmeric extract
turmeric 500 mg TID for 45 days
Other Name: turmeric
Active Comparator: ACE inhibitor + ATI blocker

diabetic nephropathy

more than 300 mg/day proteinuria

Drug: Turmeric extract
turmeric 500 mg TID for 45 days
Other Name: turmeric
Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
maximum dosage as patient tolerated for 45 days
Other Names:
  • enalapril
  • losartan

Detailed Description:

Diabetic nephropathy is leading cause of ESRF that many therapy recommended for it. In this study, we investigate effect of turmeric on diabetic nephropathy, thus we selected diabetic nephropathy patients and divided them into 2 groups. One group received turmeric + ACE inhibitor + Angiotensin II receptor blocker (ARB) and the second group received only ACE inhibitor + ARB.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • diabetic nephropathy
  • more than 300 mg proteinuria/day
  • age more than 18 years old

Exclusion Criteria:

  • DM type 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01015937

Locations
Iran, Islamic Republic of
Clinic
Shiraz, Fars, Iran, Islamic Republic of, 098
Sponsors and Collaborators
Shaheed Faghihi Hospital
Shiraz University of Medical Sciences
Investigators
Principal Investigator: maryam pakfetrat, assistant professor Shiraz nephro-urology research center
  More Information

Additional Information:
No publications provided

Responsible Party: Office of Vice Chancellor for research in Shiraz UMS, Shiraz University of Medical Science
ClinicalTrials.gov Identifier: NCT01015937     History of Changes
Other Study ID Numbers: 3997
Study First Received: November 16, 2009
Last Updated: November 17, 2009
Health Authority: Iran: Ministry of Health

Keywords provided by Shaheed Faghihi Hospital:
diabetes
nephropathy
turmeric
serum IL8
serum TGFb
serumINF
urinary IL8
urine TGFb

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Diseases
Proteinuria
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Signs and Symptoms
Urination Disorders
Urologic Diseases
Urological Manifestations
Angiotensin II
Angiotensin-Converting Enzyme Inhibitors
Turmeric extract
Antioxidants
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Protective Agents
Therapeutic Uses
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on October 23, 2014